It’s funny that they are fully funded all the way into phase 2 with non dilutive funding extending the companies funds well into phase 2 and the market cap is now trading below it’s coming up cash funding pricing nothing in for how de risked the drug is heading into phase 1 and phase 2 FDA approval. AGN is looking like on any good news will become a 200-300 million dollar company on the potential of the drug.
It’s funny that they are fully funded all the way into phase 2...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $23.05M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $90.17K | 823.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 760879 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 57758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NYR (ASX) Chart |